15 biotech IPOs have been completed thus far in the third quarter of 2014 and 61 biotech IPOs have been completed thus far in 2014 (raising approximately $4 billion in aggregate proceeds). At this pace, the biotech IPO market is on track to set new records for the number of biotech IPOs completed in the U.S. and abroad. With 30 biotech companies currently in the SEC registration process, there is no reason to believe that the number of biotech IPOs will substantially decrease in the second half of 2014. Whether these biotech companies decide to launch their offerings though will depend in part on the post-market performances of those biotech companies that have already gone public in 2014. Currently, the average share price performance of the 61 biotech companies that have gone public in 2014 stands at -4.5%, with the gainers and decliners about evenly divided. (Source: BioWorld Insight, August 11, 2014).